Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty
- Conditions
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- G. d'Annunzio University
- Target Recruit Count
- 280
- Registration Number
- NCT02205775
- Locations
- 🇮🇹
Azienda ASL 6 - P. Ospedaliero Livorno, Livorno, Italy
🇮🇹Azienda Ospedaliera - Ospedale San Paolo, Milano, Italy
🇮🇹Fondazione IRCCS Policlinico S. Matteo, Pavia, PV, Italy
Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Pontificia Universidad Catolica de Chile
- Target Recruit Count
- 20
- Registration Number
- NCT02126137
- Locations
- 🇨🇱
Department of Gastroenterology, Pontificia Universidad Católica de Chile, Santiago, Metropolitan, Chile
The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 80
- Registration Number
- NCT02103049
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
Plant Sterols Effect on Previous Statin Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Jose Rocha Faria Neto
- Target Recruit Count
- 47
- Registration Number
- NCT02089867
- Locations
- 🇧🇷
Jose Rocha Faria Neto, Curitiba, Paraná, Brazil
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 218
- Registration Number
- NCT02055976
- Locations
- 🇯🇵
Maebashi Hirosegawa Clinic, Maebashi, Gunma, Japan
🇯🇵Heishinkai Medical Group Incorporated ToCROM Clinic, Shinjuku-ku, Tokyo, Japan
🇯🇵Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 511
- Registration Number
- NCT01984424
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 45
- Registration Number
- NCT01950884
- Locations
- 🇮🇹
Dipartimento Biomedico di Medicina Interna e Specialistica Di.Bi.M.I.S., Palermo, Italy
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01941836
A Study of LY3015014 in Participants With High Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 527
- Registration Number
- NCT01890967
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Laval University
- Target Recruit Count
- 20
- Registration Number
- NCT01849068
- Locations
- 🇨🇦
Laval University, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.